Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL
NCT07012980Phase 2Recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Jun 2025
- Primary completion
- Mar 2027
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
A Phase 2 trial of glofitamab, polatuzumab vedotin, zanubrutinib in diffuse large B-cell lymphoma (DLBCL), sponsored by Zhongshan Hospital, Fudan University. Started Jun 2025; status: recruiting.
02
Drugs
glofitamabpolatuzumab vedotinzanubrutinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT07012980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07012980.